Janssen-Cilag Ltd

50 - 100 Holmers Farm Way, High Wycombe, Bucks, HP12 4EG
Telephone: +44 (0)1494 567 567
Fax: +44 (0)1494 567 568
WWW: http://www.janssen-cilag.co.uk
Medical Information Direct Line: +44 (0)800 731 8450
Medical Information e-mail: medinfo@janssen-cilag.co.uk
Customer Care direct line: +44 (0)800 731 5550
Summary of Product Characteristics last updated on the eMC: 17/02/2009
SPC Cilest

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 17/02/2009 and displayed until Current
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   11-Feb-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Change to section 7 - New MAH address
Change to section 10 - Changed to 11 February 2009
Updated on 14/01/2009 and displayed until 17/02/2009
Reasons for adding or updating:
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   07-Jan-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Change to section 9 - Date of the Renewal Authorisation
Change to section 10 - Changed to 07th January 2009
Updated on 27/08/2004 and displayed until 14/01/2009
Reasons for adding or updating:
  • Change to section 2 - qualitative and quantitative composition
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.2 - Pharmacokinetic Properties
  • Change to section 5.3 - Preclinical Safety Data
  • Change to section 10 (date of (partial) revision of the text
Updated on 02/07/2002 and displayed until 27/08/2004
Reasons for adding or updating:
  • Change to section 4.3 - Contra-indications
  • Change to section 4.4 - Special Warnings and Precautions for Use
Updated on 29/08/2001 and displayed until 02/07/2002
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 24/08/2001 and displayed until 29/08/2001
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 31/10/2000 and displayed until 24/08/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 11/08/2000 and displayed until 31/10/2000
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   ethinylestradiol
   norgestimate


© 2009 Datapharm Communications Ltd

Go to www.medicines.org.uk